SCHEMBL2958185

SCHEMBL2958185

O=S(=O)(c1ccccc1)n1nnc2ccccc21.[Pt]

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.97
CYP2C19 P33261 1/20 0.74
LMNA P02545 1/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.57
ALDH1A1 P00352 1/20 0.56
TSHR P16473 4/20 0.55
KMT2A Q03164 2/20 0.55
HSD17B10 Q99714 2/20 0.55
POLB P06746 1/20 0.53
MEN1 O00255 1/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 2/20 0.51
SMN1; SMN2 Q16637 5/20 0.50
GAA P10253 1/20 0.49
KDM4E B2RXH2 1/20 0.49
CXCL8 P10145 1/20 0.47
NOD1 Q9Y239 1/20 0.47
CRHBP P24387 1/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479875 0.98 SLC9A1 (1.00) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL2491809 0.98 SLC9A1 (1.00) SLC9A1CYP2C19LMNAHPGDHTT
Ammonia Solution, Strong SCHEMBL3379015 0.91 SLC9A1 (0.85) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL7741924 0.85 CYP2C19 (1.00) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL7746353 0.85 SLC9A1 (1.00) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL4339723 0.83 SLC9A1 (0.72) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL29479890 0.83 SLC9A1 (0.72) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL11439834 0.82 SLC9A1 (0.70) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL7746984 0.82 SLC9A1 (0.72) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL19911490 0.80 SLC9A1 (0.69) SLC9A1CYP2C19LMNAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759488-B2 Monoazole ligand platinum analogs BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-07-20 US claimed
EP-1896491-B1 MONOAZOLE LIGAND PLATINUM ANALOGS BIONUMERIK PHARMACEUTICALS INC (US) 2010-11-17 EP disclosed
US-7759488-B2 Monoazole ligand platinum analogs BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-07-20 US disclosed
CN-101495459-A Monoazole ligand platinum analogs BIONUMERIK PHARMACEUTICALS INC (US) 2009-07-29 CN disclosed
US-20070004696-A1 cis-aminedichloro [1-(phenylsulfonyl)-1H-benzotriazole] platinum for complexing with DNA and/or RNA BIONUMERIK PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004696-A1 cis-aminedichloro [1-(phenylsulfonyl)-1H-benzotriazole] platinum for complexing with DNA and/or RNA POLRMT, LUC7L2, NSUN3 SLC9A1 1266/4885CYP2C19 4818/4885LMNA 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.